Literature DB >> 27435583

Hemorrhagic Complications of Percutaneous Cryoablation for Renal Tumors: Results from a 7-year Prospective Study.

Bharat Kakarala1, Constantine E Frangakis2, Ron Rodriguez3, Christos S Georgiades4.   

Abstract

PURPOSE: Cryoablation of renal tumors is assumed to have a higher risk of hemorrhagic complications compared to other ablative modalities. Our purpose was to establish the exact risk and to identify hemorrhagic risk factors.
MATERIALS AND METHODS: This IRB approved, 7-year prospective study included 261 renal cryoablations. Procedures were under conscious sedation and CT guidance. Pre- and postablation CT was obtained, and hemorrhagic complications were CTCAE tabulated. Age, gender, tumor size, histology, and probes number were tested based on averages or proportions using their exact permutation distribution. "High-risk" subgroups (those exceeding the thresholds of all variables) were tested for each variable alone, and for all combinations of variable threshold values. We compared the subgroup with the best PPV using one variable, with the subgroup with the best PPV using all variables (McNemmar test).
RESULTS: The hemorrhagic complication rate was 3.5 %. Four patients required transfusions, two required emergent angiograms, one required both a transfusion and angiogram, and two required bladder irrigation for outlet obstruction. Perirenal space hemorrhage was more clinically significant than elsewhere. Univariate risks were tumor size >2 cm, number of probes >2, and malignant histology (P = 0.005, 0.002, and 0.033, respectively). Multivariate analysis showed that patients >55 years with malignant tumors >2 cm requiring 2 or more probes yielded the highest PPV (7.5 %).
CONCLUSIONS: Although older patients (>55 years old) with larger (>2 cm), malignant tumors have an increased risk of hemorrhagic complications, the low PPV does not support the routine use of embolization. Percutaneous cryoablation has a 3.5 % risk of significant hemorrhage, similar to that reported for other types of renal ablative modalities.

Entities:  

Keywords:  Ablation; Cryoablation; Hemorrhage; Percutaneous; RCC; Renal cancer

Mesh:

Year:  2016        PMID: 27435583     DOI: 10.1007/s00270-016-1419-x

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

Review 1.  Role of Angio-Embolization for Renal Cell Carcinoma.

Authors:  Andrew J Gunn; Anand R Patel; Soroush Rais-Bahrami
Journal:  Curr Urol Rep       Date:  2018-08-08       Impact factor: 3.092

2.  Transarterial embolization of renal cell carcinoma as an adjunctive therapy prior to cryoablation: a propensity score matching analysis.

Authors:  Andrew J Gunn; Benjamin J Mullenbach; May M Poundstone; Jennifer B Gordetsky; Edgar S Underwood; Soroush Rais-Bahrami
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

3.  Expanding thermal ablation to the 'intermediate-sized' renal mass: clinical utility in T1b tumors.

Authors:  Ariel A Schulman; Kae Jack Tay; Thomas J Polascik
Journal:  Transl Androl Urol       Date:  2017-02

4.  Sunitinib maleate administration before percutaneous CT-guided cryoablation for large renal cell carcinoma: A case report.

Authors:  Kaori Nishizawa; Tetsuya Katsumori; Yuya Kotera; Tatsuya Yoshikawa; Tomoaki Nishimura
Journal:  Radiol Case Rep       Date:  2022-10-08

5.  Percutaneous CT-Guided Renal Cryoablation: Technical Aspects, Safety, and Long-Term Oncological Outcomes in a Single Center.

Authors:  Stefano Cernic; Cristina Marrocchio; Riccardo Ciabattoni; Ilaria Fiorese; Fulvio Stacul; Fabiola Giudici; Michele Rizzo; Maria Assunta Cova
Journal:  Medicina (Kaunas)       Date:  2021-03-20       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.